|06-18-2018 01:15 PM CET - Health & Medicine||
Global Cancer Profiling Market Research Report with Key Players Analysis, Trends and Growth Forecast till 2026
Press release from: Fact.MR
FACT.MR has been actively involved in offering comprehensive research data concerning various topics which are associated to industrial reference and investor utility. This particular research report titled “Cancer Profiling Market Forecast, Trend Analysis & Competition Tracking – Global Review 2017 to 2026” has been added to the wide online database of FACT.MR which discusses the present as well as future market scenario. Readers can access knowledge related to market volume, regional expanse as well as competitive landscape prevailing in the global Cancer Profiling Market. In order to study development patterns, this smart assessment also focuses on market dynamics, which talks about drivers, restraints and opportunities estimated to influence the concerned market during the period until 2026.
Request For Sample Report @ www.factmr.com/connectus/sample?flag=S&rep_id=358
Cancer profiling offers information on the gene causing cancer along with the key insights on the mechanism of cancer. The U.S. Food and Drug Administration (FDA) recently approved first-of-its-kind cancer gene profiling. The test looks for mutations in various cancer genes at once, offering a complete profile on driving forces of tumor in patients. The key companies in the cancer profiling are coming up with new products to meet the requirements of life science and molecular diagnostics companies. The market for cancer profiling is also seeing an increase in demand for Next-Generation Sequencing (NGS). Pharmaceutical companies are also using molecular profiling through NSG to produce therapeutic vaccines for cancer.
According to a study by Fact.MR, the global market for cancer profiling is likely to experience solid growth. The global market for cancer profiling is also projected to bring in US$ 122,129.6 million revenue by 2026 end. Technological advancements, increasing cancer incidences, tumor profiling using biomarkers, the rise in funds for cancer research, are some of the major factors resulting in the growth of cancer profiling market. However, lack of skilled professionals and infrastructure are hampering the growth of the global market for cancer profiling.
Next-Generation Sequencing to Emerge as the Most-Preferred Technique in Cancer Profiling
Next-generation sequencing technique is likely to be the most-preferred cancer profiling technique. Experiencing a solid growth, next-generation sequencing technique is projected to exceed US$ 61,900 million revenue by 2026 end. Owing to the reduced sequencing cost, technology advancements in platforms used for sequencing, and rising awareness on next-generation sequencing services and products, the next-generation sequencing technique will experience growth in the market.
Cancer Profiling to Find Largest Application in Diagnosis
Cancer profiling is used for research, prognosis, personalized medicine, biomarker discovery. However, cancer profiling is likely to find the largest application in diagnosis. Gaining considerable growth, diagnosis is anticipated to create an absolute dollar opportunity of over US$ 32,200 million between 2017 and 2026. Cancer profiling plays an important role in diagnosis, as it helps physicians in understanding cancer tumor and identifying type of cancer. It also helps in taking appropriate decisions, avoiding ‘over-treatment’ of cancer patients.
Browse Full Report with TOC @ www.factmr.com/report/358/cancer-profiling-market
Pharmaceutical and Biotech Companies to Emerge as the Biggest End-User
Compared to the various end-users of cancer profiling, pharmaceutical and biotech companies are likely to emerge as the biggest users of cancer profiling. Pharmaceutical and biotech companies are projected to create an incremental opportunity surpassing US$ 40,600 million between 2017 and 2026. Factors such as offering better-targeted therapy and medicine for cancer treatment, correct prediction of various types of cancer, and reducing adverse drug reaction by offering correct dosage and formulation are driving the use of cancer profiling by pharmaceutical and biotech companies.
The report also profiles companies that are expected to remain active in the expansion of global cancer profiling market through 2026, which include Agendia, Genomic Health Inc., Oxford Gene Technology Ltd., NeoGenomics Laboratories, RiboMed Biotechnologies Inc., BioTheranostics, Proteome Sciences PLC, Illumina, Inc. (U.S.), GenScript, Caris Life Sciences, and Roche Holdings.
Buy Now @ www.factmr.com/checkout/358/S
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare Market Research Reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852
Follow us on LinkedIn: www.linkedin.com/company/factmr/
This release was published on openPR.
News-ID: 1086258 • Views: 101More releases